Loading patent…
AssigneeKorea Research Institute of Bioscience and Biotechnology
InventorsSei Ryang Oh, Kyung Seop Ahn, Hyeong Kyu Lee, Ha Young Jang, Ok-Kyoung Kwon, Jung Hee Kim, Ji Won Park, Doo-Young Kim
Estimating the term…
The present invention relates to a pharmaceutical composition for the prevention or treatment of asthma comprising Wogonin as an active ingredient. The Wogonin of the present invention is excellent not only in relieving airway hypersensitivity that causes asthma in vivo, in inhibiting reactive oxygen species generation in the airway, and in inhibiting the infiltration of inflammatory cells in the bronchus, but also in inhibiting the generation of IgE in serum and bronchoalveolar lavage fluid, and in inhibiting the expressions of Th2 cytokines in the lung. Therefore, the Wogonin of the present invention can be effectively used as a composition for the prevention, treatment, or improvement of asthma.
1-10. (canceled)
A method for treating asthma comprising administering to a subject in need thereof a pharmaceutically effective amount of Wogonin represented by the following formula 1,
A method for alleviating airway hypersensitivity or inhibiting reactive oxygen generation in the airway comprising administering to a subject in need thereof a pharmaceutically effective amount of Wogonin represented by the following formula 1,
A method for reducing the number of inflammatory cells in the bronchus, the concentration of IgE antibody in serum, or the expression of Th2 cytokine comprising administering to a subject in need thereof a pharmaceutically effective amount of Wogonin represented by the following formula 1,
Dependencies are inferred from the claim text.